» Authors » Christine E Engeland

Christine E Engeland

Explore the profile of Christine E Engeland including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 36
Citations 776
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Schafer T, Knol L, Haas F, Hartley A, Pernickel S, Jady A, et al.
EBioMedicine . 2024 Jun; 105:105219. PMID: 38941955
Background: Pancreatic ductal adenocarcinoma (PDAC) is a tumour entity with unmet medical need. To assess the therapeutic potential of oncolytic virotherapy (OVT) against PDAC, different oncolytic viruses (OVs) are currently...
2.
Goyvaerts C, Engeland C, Van der Jeught K
Front Immunol . 2023 Nov; 14:1326374. PMID: 38022618
No abstract available.
3.
Anker S, Szczeponik M, Dessila J, Dittus K, Engeland C, Jager D, et al.
Viruses . 2023 Feb; 15(2). PMID: 36851522
Virotherapy is a promising, novel form of cancer immunotherapy currently being investigated in pre-clinical and clinical settings. While generally well-tolerated, the anti-tumor potency of oncolytic virus-based monotherapies needs to be...
4.
Floerchinger A, Klein J, Finkbeiner M, Schafer T, Fuchs G, Doerner J, et al.
Cell Death Dis . 2023 Feb; 14(2):104. PMID: 36765035
Treatment with oncolytic measles vaccines (MV) elicits activation of immune cells, including natural killer (NK) cells. However, we found that MV-activated NK cells show only modest direct cytotoxic activity against...
5.
Veinalde R, Pidelaserra-Marti G, Moulin C, Tan C, Schafer T, Kang N, et al.
Front Immunol . 2023 Feb; 13:1096162. PMID: 36726983
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is largely refractory to cancer immunotherapy with PD-1 immune checkpoint blockade (ICB). Oncolytic virotherapy has been shown to synergize with ICB. In this work, we...
6.
7.
Floerchinger A, Engeland C
Methods Mol Biol . 2022 Jun; 2521:233-248. PMID: 35733001
Oncolytic virotherapy is a compelling strategy to combine cancer gene therapy with immunotherapy. Lytic virus replication in malignant cells not only enables localized transgene expression based on engineered vectors but...
8.
Russell S, Bell J, Engeland C, McFadden G
Commun Med (Lond) . 2022 May; 2:33. PMID: 35603308
Recent years have seen rapid advances in the preclinical development and clinical evaluation of oncolytic (cancer-lysing) virus-based therapies, and these are emerging as treatment modality for some cancers. There are...
9.
Veinalde R, Pidelaserra-Marti G, Moulin C, Jeworowski L, Kuther L, Buchholz C, et al.
Mol Ther Oncolytics . 2022 Jan; 24:43-58. PMID: 34977341
PD-1/PD-L1 checkpoint blockade has achieved unprecedented success in cancer immunotherapy. Nevertheless, many immune-excluded tumors are resistant to therapy. Combination with oncolytic virotherapy may overcome resistance by inducing acute inflammation, immune...
10.
Aydin M, Dietrich J, Witt J, Finkbeiner M, Park J, Wirth S, et al.
Int J Mol Sci . 2021 Dec; 22(23). PMID: 34884799
There is a lack of knowledge regarding the connection between the ocular and nasal epithelia. This narrative review focuses on conjunctival, corneal, ultrastructural corneal stroma, and nasal epithelia as well...